Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $521 | $221 | $216 | $223 |
| - Cash | $153 | $187 | $217 | $153 |
| + Debt | $7 | $8 | $107 | $8 |
| Enterprise Value | $375 | $42 | $106 | $78 |
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -$1 | $1 | -$1 | -$1 |
| % Margin | – | 49.1% | – | -589% |
| EBITDA | -$31 | -$25 | -$40 | -$47 |
| % Margin | – | -1,911.5% | – | -47,176% |
| Net Income | -$35 | -$29 | -$43 | -$48 |
| % Margin | – | -2,204.2% | – | -47,865% |
| EPS Diluted | -2.28 | -1.85 | -2.8 | -3.31 |
| % Growth | -23.2% | 33.9% | 15.4% | – |
| Operating Cash Flow | -$34 | -$30 | -$36 | -$44 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$34 | -$30 | -$36 | -$44 |